Irish companies perform well in financial review of European biotech
industry
A review of the financial results of both publicly quoted and private
European biotechnology companies contained encouraging news for Ireland.
Performed and published by Nature Biotechnology this autumn, the review
shows 2 Irish companies, (Elan and Trinity Biotech) in the top 20
publicly listed companies examined. The 20 companies are dominated by
those from the UK, (12) with an additional 2 from Denmark, and one each
from France, Germany, Belgium and Switzerland while Elan and Trinity
Biotech are at numbers 3 and 19 respectively. The top company was
Novo-Nordisk, (Denmark) with 1996 revenues of 1915.6 million ECUs.
An additional survey of private European biotechnology companies
showed the Irish company Biotrin Holdings at number 11. The top company
in this sector was BioMerieux, (France) with a 1996 revenue of 417
million ECUs. The review showed that the results of the examined
companies were up 12.65 compared to 1995 and that 3 companies account
for more than 80% of European biotechnology company revenue. They are
Novo-Nordisk, Ares-Serono, (Switzerland) and BioMerieux.
Full details in: "European biotechnology companies grow by 12.6%"
Lahtteenmaki, R., pp: 6-9, Nature Biotechnology, EuroProduct Focus,
Autumn 1997. |
